SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.
|Journal||Annals of Internal Medicine|
|Publication status||Published - 1 Oct 2022|